CARY, NC – Trana Discovery Inc., an infectious disease drug discovery technology company, has formed a Scientific Advisory Board that will advise the company on the needs of the infectious disease community and on the development of assays to discover new medicines for the treatment of serious bacterial, viral, and fungal infectious diseases.
Pharmaceutical industry veteran Dr. Michael Ossi will serve as the new board’s chair.
Trana Discovery assays identify new drug compounds that work through a unique mechanism of action: inhibition of the target pathogen’s ability to use transfer RNA (tRNA) essential for propagation.
Dr. Ossi built and maintained a large pediatric practice while concurrently serving as a faculty advisor for the University of Massachusetts Medical School residency program. In 1988, he accepted a position at Glaxo Inc. and spent the next 18 years in clinical drug development at the director and VP levels, managing programs in various viral and bacterial diseases and several oncology programs.
Dr. Ossi was Vice President, Infectious Diseases, Medicine Development at GlaxoSmithKline before retiring in 2007.
Online: www.tranadiscovery.com
Join hundreds of Marketing Professionals and Internet Execs at Atlanta’s premier Digital event – Digital Summit 2012
www.digitalsummit.com
Related Stories:
- Trana Discovery grabs $720K to hunt down new drugs
- Tranzyme gets $300k in grants
- NC Biotech Center awards $1.3M in loans to 5 biotech startups
- Emory, Zirus Inc. developing new type of anti-viral drugs
- Florida’s Viragen closes $3 million private placement
© 2009, TechJournal. All rights reserved.
